MYND Life Sciences Inc. (MYND.CN)
CAD 0.07
(0.0%)
CAD 0.07
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | - CAD | -100.0% |
| 2022 | 59.53 Thousand CAD | -97.36% |
| 2021 | 2.25 Million CAD | 0.0% |
| 2020 | - CAD | 0.0% |
| 2019 | - CAD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | - CAD | 0.0% |
| 2024 Q1 | - CAD | 0.0% |
| 2024 Q3 | - CAD | 0.0% |
| 2023 Q3 | - CAD | 0.0% |
| 2023 FY | - CAD | -100.0% |
| 2023 Q4 | - CAD | 0.0% |
| 2023 Q2 | - CAD | -100.0% |
| 2023 Q1 | 46.8 Thousand CAD | -21.39% |
| 2022 Q1 | 2.35 Million CAD | 4.3% |
| 2022 FY | 59.53 Thousand CAD | -97.36% |
| 2022 Q4 | 59.53 Thousand CAD | -97.55% |
| 2022 Q3 | 2.42 Million CAD | 4.93% |
| 2022 Q2 | 2.31 Million CAD | -1.59% |
| 2021 Q1 | 312.01 Thousand CAD | 0.0% |
| 2021 Q4 | 2.25 Million CAD | 734.94% |
| 2021 Q2 | 287.68 Thousand CAD | -7.8% |
| 2021 FY | 2.25 Million CAD | 0.0% |
| 2021 Q3 | 269.91 Thousand CAD | -6.18% |
| 2020 FY | - CAD | 0.0% |
| 2019 FY | - CAD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | - CAD | NaN% |
| Asep Medical Holdings Inc | - CAD | NaN% |
| BetterLife Pharma Inc. | 245.23 Thousand CAD | 100.0% |
| BioVaxys Technology Corp. | - CAD | NaN% |
| ChitogenX Inc. | 3.27 Million CAD | 100.0% |
| Rapid Dose Therapeutics Corp. | 2.12 Million CAD | 100.0% |
| Defence Therapeutics Inc. | 7871.00 CAD | 100.0% |
| Entheon Biomedical Corp. | - CAD | NaN% |
| Gemina Laboratories Ltd. | 205.98 Thousand CAD | 100.0% |
| Glow Lifetech Corp. | - CAD | NaN% |
| Lexston Life Sciences Corp. | - CAD | NaN% |
| Pharmala Biotech Holdings Inc. | - CAD | NaN% |
| Doseology Sciences Inc. | - CAD | NaN% |
| Nova Mentis Life Science Corp. | - CAD | NaN% |
| PharmaTher Holdings Ltd. | - CAD | NaN% |
| PreveCeutical Medical Inc. | - CAD | NaN% |
| Telescope Innovations Corp. | - CAD | NaN% |